Enliven Therapeutics Inc (ELVN) Stock Price, Quote & News

Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and...

Industry: Biotechnology

Sector: Healthcare

Phone: 720 647 8519

Website: www.enliventherapeutics.com

Address:

6200 Lookout Road, Boulder, United States

justiceforb_85 Jan. 28 at 2:59 AM

$ELVN remains undervalued.

0 · Reply

OfficialStocktwitsUser Jan. 23 at 3:37 AM

$ELVN RSI: 85.29, MACD: 2.3782 Vol: 5.28, MA20: 20.85, MA50: 20.33 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Sw1ngb0t Jan. 23 at 1:10 AM

$ELVN $32.29+

0 · Reply

thedentite Jan. 22 at 3:14 PM

$ELVN Big green candle. Nice

0 · Reply

thedentite Jan. 21 at 6:41 PM

$ELVN I love the gentle movement up.

1 · Reply

thedentite Jan. 16 at 6:38 PM

$ELVN Bearish sentiment? Ha

1 · Reply

blue81 Jan. 16 at 6:52 AM

$ELVN 33$ is coming in this quarter

0 · Reply

Jimbates22 Jan. 14 at 6:45 PM

$ELVN green to red. A sign that the pump is over.

0 · Reply

Jimbates22 Jan. 14 at 5:51 PM

$ELVN looks like they are setting up for an offering. Insiders dumping

1 · Reply

johnmidland Jan. 14 at 3:50 PM

$ELVN so all the insiders are dumping their shares hand over fist and we are somehow holding $26? SMH

1 · Reply

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

Jan 8, 2026, 9:00 AM EST - 19 days ago

Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones

Jan 7, 2026, 9:00 AM EST - 20 days ago

Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development

Dec 11, 2025, 4:21 PM EST - 6 weeks ago

Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Dec 11, 2025, 9:00 AM EST - 6 weeks ago

Enliven Therapeutics Announces New CEO to Drive Next Phase of Development

Nov 18, 2025, 7:55 AM EST - 2 months ago

Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy

Nov 12, 2025, 4:05 PM EST - 2 months ago

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

Aug 25, 2025, 6:20 PM EDT - 5 months ago

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

Aug 13, 2025, 4:05 PM EDT - 5 months ago

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Jun 16, 2025, 4:05 PM EDT - 8 months ago

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 13, 2025, 9:30 AM EDT - 8 months ago

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:10 AM EDT - 8 months ago

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jun 13, 2025, 6:02 AM EDT - 8 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

May 22, 2025, 4:05 PM EDT - 8 months ago

Enliven Therapeutics to Present at Upcoming Investor Conferences

May 14, 2025, 4:05 PM EDT - 9 months ago

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

May 14, 2025, 9:56 AM EDT - 9 months ago

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

Apr 2, 2025, 4:03 PM EDT - 10 months ago

Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

Mar 21, 2025, 6:38 PM EDT - 11 months ago

Final Trade: CVX, XLE, ELVN, COF

CVX XLE COF

Mar 13, 2025, 4:05 PM EDT - 11 months ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 25, 2025, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

DCTH IBB

Jan 7, 2025, 12:28 AM EST - 1 year ago

Enliven's Early Data Stands Out From Peers

Nov 7, 2024, 4:05 PM EST - 1 year ago

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference

Oct 18, 2024, 7:18 PM EDT - 1 year ago

Why Enliven is this analyst's top biotech stock pick

Sep 28, 2024, 9:35 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML

May 29, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Apr 11, 2024, 7:55 AM EDT - 1 year ago

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024

Mar 19, 2024, 8:30 AM EDT - 2 years ago

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Feb 27, 2024, 4:05 PM EST - 2 years ago

Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference

Aug 18, 2023, 12:57 PM EDT - 2 years ago

Enliven Therapeutics: Preclinical Company With Interesting Value Proposition

Aug 10, 2023, 4:05 PM EDT - 2 years ago

Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Feb 23, 2023, 5:20 PM EST - 3 years ago

Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million

Feb 22, 2023, 4:01 PM EST - 3 years ago

Imara Announces Stockholder Approval of Merger With Enliven

Jan 25, 2023, 1:07 PM EST - 3 years ago

IMARA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Imara Inc. - IMRA

Oct 13, 2022, 4:35 PM EDT - 3 years ago

Enliven Therapeutics and Imara Announce Merger Agreement

Sep 29, 2022, 3:06 PM EDT - 3 years ago

Imara: Potential Liquidation

Apr 5, 2022, 10:13 AM EDT - 4 years ago

Read Why Imara Shares Are Falling Today

Apr 5, 2022, 6:45 AM EDT - 4 years ago

Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia

Mar 15, 2022, 11:06 AM EDT - 4 years ago

Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript

Mar 8, 2022, 7:00 AM EST - 4 years ago

Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights

Feb 10, 2022, 7:00 AM EST - 4 years ago

Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference

Jan 25, 2022, 11:03 AM EST - 4 years ago

Imara To Start Testing Tovinontrine In Heart Failure Patients

Jan 25, 2022, 7:00 AM EST - 4 years ago

Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)

Jan 5, 2022, 7:00 AM EST - 4 years ago

Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

justiceforb_85 Jan. 28 at 2:59 AM

$ELVN remains undervalued.

0 · Reply

OfficialStocktwitsUser Jan. 23 at 3:37 AM

0 · Reply

Sw1ngb0t Jan. 23 at 1:10 AM

$ELVN $32.29+

0 · Reply

thedentite Jan. 22 at 3:14 PM

$ELVN Big green candle. Nice

0 · Reply

thedentite Jan. 21 at 6:41 PM

$ELVN I love the gentle movement up.

1 · Reply

thedentite Jan. 16 at 6:38 PM

$ELVN Bearish sentiment? Ha

1 · Reply

blue81 Jan. 16 at 6:52 AM

$ELVN 33$ is coming in this quarter

0 · Reply

Jimbates22 Jan. 14 at 6:45 PM

$ELVN green to red. A sign that the pump is over.

0 · Reply

Jimbates22 Jan. 14 at 5:51 PM

$ELVN looks like they are setting up for an offering. Insiders dumping

1 · Reply

johnmidland Jan. 14 at 3:50 PM

$ELVN so all the insiders are dumping their shares hand over fist and we are somehow holding $26? SMH

1 · Reply

Quantumup Jan. 13 at 8:45 PM

William Blair reiterated $TERN Outperform/Top Pick. $NVS $ELVN William Blair said in its note: Following the company's presentation last year at the American Society of Hematology (ASH) annual meeting, it is our view that "unprecedented" remains the only suitable adjective to describe the clinical activity of TERN-701 in third-line or later chronic myeloid leukemia (CML). It is rare for an investigational agent to demonstrate unequivocal improvement in both clinical efficacy and safety and concurrently provide patients with better convenience of daily dosing with no food effect. William Blair went on to say: https://x.com/Quantumup1/status/2011175547691548887?s=20

0 · Reply

thedentite Jan. 13 at 4:08 PM

$ELVN Back in the right direction. I see a bright future

0 · Reply

Stackdoe1 Jan. 13 at 3:41 PM

$ELVN $40

0 · Reply

StockScanners Jan. 13 at 5:26 AM

$ELVN reached 29.98

0 · Reply

tt01 Jan. 12 at 9:58 AM

$ELVN $APLD $CRML $MRNO $RGC

0 · Reply

PaulLaurent Jan. 12 at 7:45 AM

🔥 Short Squeeze Candidates → this week (ORTEX) $ELVN — short score 72.81/100 Fresh: initial Phase 1b ELVN-001 data in CML; company outlined 2026 milestones (dose/Phase 3 planning). $APLD — short score 69.51/100 Fresh: Q2 FY26 beat and management says it’s in advanced talks with an IG hyperscaler (up to ~900MW) after recently closing $2.35B notes. $CRML — short score 76.81/100 Fresh: update pointed to a pilot plant target around May 2026 and expectations for early-2026 offtake progress. $MRNO — short score 80.03/100 No new company headlines in the last 72h; setup driven by elevated short interest and thin float dynamics. $RGC — short score 93.55/100 Fresh: shares gapped on Jan 10 after recent volatility—watch for event-driven spikes and borrow swings. Notes: Scores are from ORTEX. As always, this is not financial advice—use tight risk and plan entries/exits. 🚦

0 · Reply

Jimbates22 Jan. 9 at 9:11 PM

$MLTX oh yeah next week this one is higher than $ELVN

0 · Reply

Jimbates22 Jan. 9 at 6:48 PM

$MLTX and $ELVN will switch prices next week

0 · Reply

Jimbates22 Jan. 9 at 6:16 PM

$ELVN huge overreaction on a light volume pump. Will come back down next week to around $20

0 · Reply

johnmidland Jan. 9 at 5:36 PM

$ELVN This looks like its about to take a major dump

0 · Reply

outlawinvestor1 Jan. 9 at 5:05 PM

$TERN be careful with new $ELVN data. https://www.oncologypipeline.com/apexonco/node/1826

2 · Reply

Aburose Jan. 9 at 4:09 PM

$ELVN to day all market very good esp today friday maybe they change there strategy

0 · Reply

Market Cap	1.54B
Revenue (ttm)	0.00
Net Income (ttm)	-89.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	642,300
Avg Vol	1,043,432
Day's Range	N/A - N/A
Shares Out	59.35M
Stochastic %K	43%
Beta	0.41
Analysts	Strong Sell
Price Target	$40.78